Medical-device maker Misonix said it voluntarily contacted the Securities and Exchange Commission and the U.S. Department of Justice this week to inform them about potential violations of the Foreign Corrupt Practices Act.
“The company may have had knowledge of certain business practices of the independent Chinese entity that distributes its products in China,” Misonix said a Sept. 28 Form 8-K filing.
The audit committee of the board engaged outside counsel to conduct an internal investigation to review these and other matters, the company said. “The internal investigation is ongoing.”
Misonix added that it “has no current information derived from the investigation to date or otherwise to suggest that its previously reported financial statements and results are incorrect in any material respect.”
The company said it intends to cooperate fully with the Justice Department and SEC as the investigation continues.